CAJ | 학술논문

目的：探讨苏盂鲁司特钠联合布地奈德气雾剂对咳嗽变异型哮喘( CVA)的临床治疗作用。方法81例符合咳嗽变异性哮喘诊断标准的患者随机分为观察组42例，给予布地奈德气雾剂吸入和盂鲁司特钠口服。对照组39例，给予布地奈德气雾剂吸入。观察治疗前、治疗4周后血清总IgE、外周血嗜酸性粒细胞计数( EOS)、肺活量( FVC)、最大呼气峰流速( PEF)的变化。结果治疗前两组患者IgE、EOS、FVC、PEF比较，差异无统计学意义(P>0．05)。治疗4周后，观察组IgE、EOS比对照组明显下降(P<0．05)；FVC、PEF明显提高(P<0．05)。结论盂鲁司特钠联合布地奈德气雾剂吸入治疗咳嗽变异型哮喘疗效显著、不良反应较少，明显改善哮喘、咳嗽等临床症状。
목적：탐토소우로사특납연합포지내덕기무제대해수변이형효천( CVA)적림상치료작용。방법81례부합해수변이성효천진단표준적환자수궤분위관찰조42례，급여포지내덕기무제흡입화우로사특납구복。대조조39례，급여포지내덕기무제흡입。관찰치료전、치료4주후혈청총IgE、외주혈기산성립세포계수( EOS)、폐활량( FVC)、최대호기봉류속( PEF)적변화。결과치료전량조환자IgE、EOS、FVC、PEF비교，차이무통계학의의(P>0．05)。치료4주후，관찰조IgE、EOS비대조조명현하강(P<0．05)；FVC、PEF명현제고(P<0．05)。결론우로사특납연합포지내덕기무제흡입치료해수변이형효천료효현저、불량반응교소，명현개선효천、해수등림상증상。
Objective To observe the clinical efficacy of montelukast combined with budesonide aerosol in the treatment of patients with cough variant asthma. Methods 81 patients with CVA were randomly divided into the study group (42 cases), which were given montelukast combined with budesonide aerosol inhalation, and the control group (39 cases), which were only given budesonide aerosol inhalation. Their clinical efficacy, IgE, EOS, FVC and PEF were recorded and analyzed before and 4 weeks after the treatment. Results There was no significant difference in IgE, EOS, FVC and PEF between the two groups before the treatment (P>0. 05). The expression of IgE and EOS decreased more significantly in the study group than in the control group 4 weeks after the treatment ( P <0. 05 ) , and the value of FVC and PEF increased more significantly in the study group than in the control group ( P<0. 05). Conclusion Montelukast sodium combined with budesonide inhalation can greatly improve the clinical symptoms, such as asthma and cough, and there is less adverse reaction in the treatment of patients with CVA.